Economic burden of diabetes in Brazil in 2014
Nenhuma Miniatura disponível
Data
2019
Título da Revista
ISSN da Revista
Título de Volume
Editor
Resumo
Background: Diabetes and its complications produce signifcant clinical, economic and social impact. The knowl edge of the costs of diabetes generates subsidies to maintain the fnancial sustainability of public health and social
security systems, guiding research and health care priorities.
Aims: The aim of this study was to estimate the economic burden of diabetes in Brazilian adults in 2014, considering
the perspectives of the public health care system and the society.
Methods: A prevalence-based approach was used to estimate the annual health resource utilization and costs
attributable to diabetes and related conditions. The healthcare system perspective considered direct medical costs
related to outpatient and hospitalization costs. The societal perspective considered non-medical (transportation and
dietary products) and indirect costs (productivity loss, disability, and premature retirement). Outpatient costs included
medicines, health professional visits, exams, home glucose monitoring, ophthalmic procedures, and costs related to
end stage renal disease. The costs of hospitalization attributed to diabetes related conditions were estimated using
attributable risk methodology. Costs were estimated in Brazilian currency, and then converted to international dollars
(2014).
Results: Based on a national self-reported prevalence of 6.2%, the total cost of diabetes in 2014 was Int$ 15.67 billion,
including Int$ 6.89 billion in direct medical costs (44%), Int$ 3.69 billion in non-medical costs (23.6%) and Int$ 5.07
billion in indirect costs (32.4%). Outpatient costs summed Int$ 6.62 billion and the costs of 314,334 hospitalizations
attributed to diabetes and related conditions was Int$ 264.9 million. Most hospitalizations were due to cardiovascu lar diseases (47.9%), followed by diabetes itself (18%), and renal diseases (13.6%). Diet and transportation costs were
estimated at Int$ 3.2 billion and Int$ 462.3 million, respectively.
Conclusions: Our results showed a substantial economic burden of diabetes in Brazil, and most likely are underrated
as they are based on an underestimated prevalence of diabetes. Healthcare policies aiming at diabetes prevention
and control are urgently sought.
Descrição
Palavras-chave
Type 2 diabetes, Cost analysis, Cost studies, Public health
Citação
BAHIA, Luciana Ribeiro et al. Economic burden of diabetes in Brazil in 2014. Diabetology & Metabolic Syndrome, London, v. 11, p. 54, 2019. DOI: 10.1186/s13098-019-0448-4. Disponível em: https://dmsjournal.biomedcentral.com/articles/10.1186/s13098-019-0448-4. Acesso em: 4 dez. 2024.